Heparin Sodium Injection
Heparin Sodium Injection - Related Videos
05:58
Retinal Detachment Model in Rodents by Subretinal Injection of Sodium Hyaluronate
0 Views •
Cited by 44 •
2013
Creating experimental retinal detachments with a reproducible and sustained height of detachment, and without subretinal hemorrhage, is important for studying the pathophysiology of photoreceptor cell loss in retinal disease and evaluating potential therapeutic interventions. Here, we report such a method in detail.
02:21
Purification of Viral Integrase Using Heparin Affinity Chromatography
0 Views •
2026
Source: Lopez Jr., M. et al. Detection and Removal of Nuclease Contamination During Purification of Recombinant Prototype Foamy Virus Integrase. J. Vis. Exp. (2017)This video demonstrates the procedure for purifying viral integrase from bacterial nuclease contamination using heparin Sepharose column chromatography followed by SDS-PAGE analysis to confirm protein purity.
10:41
Using a GFP-tagged TMEM184A Construct for Confirmation of Heparin Receptor Identity
0 Views •
Cited by 2 •
2017
A construct encoding TMEM184A with a GFP tag at the carboxy-terminus designed for eukaryotic expression, was employed in assays designed to confirm the identification of TMEM184A as a heparin receptor in vascular cells.
12:27
Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery
0 Views •
Cited by 2 •
2016
Self-assembled polyelectrolyte complexes (PEC) fabricated from heparin and protamine were deposited on alginate beads to entrap and regulate the release of osteogenic growth factors. This delivery strategy enables a 20-fold reduction of BMP-2 dose in spinal fusion applications. This article illustrates the benefits and fabrication of PECs.
06:14
Tuina Intervention in Sodium Monoiodoacetate Injection-Induced Rat Model of Knee Osteoarthritis
0 Views •
Cited by 1 •
2024
This protocol describes the methods of Tuina intervention in sodium monoiodoacetate injection-induced rat model of knee osteoarthritis (KOA), which provides a reference for the application of Tuina in KOA animal models. This protocol also studies the effective mechanism of Tuina for KOA, and the results will help promote its application.
FAQs
Heparin sodium injection binds to antithrombin and accelerates its anticoagulant activity. This enhanced action inhibits thrombin and clotting factor Xa, two components that support fibrin development. By reducing fibrin formation, the treatment limits the development and extension of harmful clots. Its effect therefore acts on the clotting process rather than directly removing a clot that already exists.
The treatment reduces ongoing coagulation by strengthening antithrombin-mediated inhibition of thrombin and factor Xa. Because this action suppresses additional fibrin development, it can help prevent an existing clot from enlarging. It does not directly break down the clot itself, so prevention of further growth and dissolution of an established clot represent different therapeutic processes.
Heparin sodium injection can increase bleeding risk because it suppresses key steps in coagulation. Clinicians therefore commonly adjust the dose and use laboratory monitoring to assess treatment and support safer management. These measures help balance the intended reduction in clot formation against excessive anticoagulant effect, particularly when treatment is being used for active disease or prevention.
In venous thromboembolism care, heparin sodium injection may support either treatment or prophylaxis. Treatment addresses harmful clot formation that has already occurred, while prophylaxis aims to reduce the likelihood of clot development in an at-risk clinical setting. In both situations, its anticoagulant action limits fibrin formation, while monitoring and dose adjustment help manage bleeding risk.
During cardiovascular procedures, preventing clot formation can be an essential part of clinical management. Heparin sodium injection provides anticoagulant activity by inhibiting thrombin and factor Xa through antithrombin. Its use in this setting reflects the need to reduce procedure-associated clotting, while clinicians must account for its potential to increase bleeding and adjust therapy accordingly.
Hemodialysis is identified as a setting in which clot prevention is essential. Heparin sodium injection can provide anticoagulant activity during this process by limiting thrombin and factor Xa activity and reducing fibrin development. This application illustrates how the drug is used not only for venous clot management, but also when maintaining a clinical procedure requires control of coagulation.